Table 1.
Clinical characteristics of patients in cohorts 1 and 2 grouped by estrogen receptor status
| Cohort 1 (n = 379)
|
Cohort 2 (n = 209)
|
|||||
|---|---|---|---|---|---|---|
| Variable | ER+ n (%) 276 (73) |
ER− n (%) 103 (27) |
P | ER+ n (%) 185 (88) |
ER− n (%) 24 (12) |
P |
| PR | ||||||
| Positive | 229 (83) | 4 (4) | <0.001 | 167 (90) | 8 (33) | <0.001 |
| Negative | 47 (17) | 99 (96) | 18 (10) | 16 (67) | ||
| HER2 | ||||||
| Positive | 42 (15) | 37 (36) | <0.001 | 27 (15) | 13 (54) | <0.001 |
| Negative | 234 (85) | 66 (64) | 158 (85) | 11 (46) | ||
| Elston—Ellis grade | ||||||
| I | 34 (12) | 0 (0) | 0.059a | 54 (10) | 2 (8) | 0.031a |
| II | 144 (53) | 28 (27) | 103 (56) | 8 (33) | ||
| III | 95 (35) | 75 (73) | 26 (14) | 14 (59) | ||
| Missing cases = 3 | Missing cases = 2 | |||||
| Nodal status | ||||||
| Negative | 104 (38) | 49 (48) | 0.134 | 115 (64) | 14 (61) | 0.958 |
| Positive | 167 (62) | 54 (52) | 65 (36) | 9 (39) | ||
| Missing cases = 5 | Missing cases = 6 | |||||
| Tumor size | ||||||
| <20 mm | 130 (47) | 37 (36) | 0.069 | 83 (45) | 7 (29) | 0.214 |
| ≥20 mm | 144 (53) | 65 (64) | 102 (55) | 17 (71) | ||
| Missing cases = 3 | ||||||
| Age | ||||||
| <50 | 46 (37) | 19 (39) | 0.917 | 35 (19) | 4 (17) | 0.789 |
| ≥50 | 80 (63) | 30 (61) | 150 (81) | 20 (83) | ||
| Missing cases = 204 | ||||||
| Chemotherapy | ||||||
| Yes | 171 (62) | 98 (95) | <0.001 | 16 (9) | 3 (12) | 0.849 |
| No | 105 (38) | 5 (5) | 163 (91) | 21 (88) | ||
| Missing cases = 6 | ||||||
| Endocrine therapy | ||||||
| Yes | 261 (95) | 8 (8) | <0.001 | 62 (35) | 9 (37) | 0.961 |
| No | 15 (5) | 95 (92) | 117 (65) | 15 (63) | ||
| Missing cases = 6 | ||||||
| Ki67 | ||||||
| <16 | 166 (60) | 18 (17) | <0.001 | 131 (71) | 9 (37) | 0.002 |
| ≥16 | 110 (40) | 85 (83) | 54 (29) | 15 (63) | ||
NOTE: Correlations were calculated using χ2 test unless otherwise specified.
a
Wilcoxon/Mann–Whitney.